Optimizing Treatment for Chronic Hepatitis C Patients with Hepatitis C Virus Genotype 1 Infection
博士 === 國立臺灣大學 === 臨床醫學研究所 === 103 === Chronic hepatitis C virus (HCV) infection, the leading cause of cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC), affects approximately 3% of the individuals worldwide. Peginterferon (PEG-IFN) plus ribavirin (RBV) therapy (PR) is one of the c...
Main Authors: | Chen-Hua Liu, 劉振驊 |
---|---|
Other Authors: | Jia-Horng Kao |
Format: | Others |
Language: | en_US |
Published: |
2015
|
Online Access: | http://ndltd.ncl.edu.tw/handle/16276864205464839418 |
Similar Items
-
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.
by: Jonas Söderholm, et al.
Published: (2013-01-01) -
Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary
by: Raymond Odhiambo, et al. -
Histopathology of chronic hepatitis C in relation to virus genotype
by: Simonović Jasmina, et al.
Published: (2006-01-01) -
Mixed Genotype Infections with Hepatitis C Virus, Pakistan
by: Sadia Butt, et al.
Published: (2011-08-01) -
Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection
by: Smith MA, et al.
Published: (2015-11-01)